Common Stock, $0.0001 par value per share
- Symbol
- IMVT
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
Immunovant, Inc.
IMVTNASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On November 9, 2026, Immunovant, Inc. (“the Company”) issued a press release announcing its financial results for its fiscal second quarter and six months ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.…
Press release in this filing
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended September 30, 2026 →Company context
Current securities
Registered securities in this filing
IMMUNOVANT, INC. · 8-K · Filed 2026-11-09
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02. Results of Operations and Financial Condition.
On November 9, 2026, Immunovant, Inc. (“the Company”) issued a press release announcing its financial results for its fiscal second quarter and six months ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information contained in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information in this Item 2.02 shall not be incorporated by reference in any filing with the U.S. Securities and Exchange Commission, or the SEC, made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.